• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹腔内给予卡铂的效用——药代动力学分析

[Usefulness of intraperitoneal carboplatin administration-- pharmacokinetic analysis].

作者信息

Ito K, Itani Y, Furuki K, Tamori N, Noda T, Adachi S, Hirano Y, Kato Y, Kiyozuka Y

机构信息

Department of Obstetrics and Gynecology, Hyogo Prefectural Nishinomiya Hospital, Hyogo.

出版信息

Nihon Sanka Fujinka Gakkai Zasshi. 1992 Sep;44(9):1180-6.

PMID:1453047
Abstract

A bolus of carboplatin (CBDCA) 200-450mg/body (148-292mg/m2) with 500ml saline was administrated into the abdominal cavity (ip) of 4 patients with ovarian cancer and 2 patients with uterine endometrial cancer, and concentrations of free and total platinum (Pt) in the blood and ascites were measured with the passage of time. Moreover, the results were analyzed with a 2-compartment model and moment analyses in order to study in vivo kinetics of CBDCA at the time of the ip administration. 1) The shift of Pt to blood through ip administration depended on the peritoneal clearance. Cmax in blood was seen one hour after ip in patients with a normal peritoneum, and was seen between 4 and 6 hours after ip in patients with peritonitis carcinomatosa. The level was lower in the latter group. 2) The non-binding rate of Pt with protein in the ascites at the time of the ip administration was correlated with the CBDCA concentration in the ascites. 3) The non-binding rate was 80% or more both in the ascites and in the blood within 4 hours after ip. The high level of the nonbinding rate appeared to cause prolongation of the presence of the free-Pt in the ascites and blood, especially in patients with peritonitis carcinomatosa. 4) AUC level in blood was equal to or higher than that observed when the same dose was administered iv. The levels of free-Pt and AUC in the abdominal cavity were 2 to 5 times higher than those in blood in patients with a normal peritoneum, and 7 to 14 times higher in patients with peritonitis carcinomatosa.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

将200 - 450mg/体(148 - 292mg/m²)的卡铂(CBDCA)与500ml生理盐水混合,经腹腔注射(ip)给4例卵巢癌患者和2例子宫内膜癌患者,随着时间推移测量血液和腹水中游离铂(Pt)和总铂的浓度。此外,采用二室模型和矩量分析对结果进行分析,以研究腹腔注射时CBDCA的体内动力学。1)腹腔注射后铂向血液的转移取决于腹膜清除率。腹膜正常的患者腹腔注射后1小时血液中出现Cmax,癌性腹膜炎患者腹腔注射后4至6小时出现Cmax。后一组的水平较低。2)腹腔注射时腹水中铂与蛋白质的非结合率与腹水中CBDCA浓度相关。3)腹腔注射后4小时内,腹水和血液中的非结合率均为80%或更高。高非结合率似乎导致游离铂在腹水和血液中的存在时间延长,尤其是癌性腹膜炎患者。4)血液中的AUC水平等于或高于静脉注射相同剂量时观察到的水平。腹膜正常的患者腹腔内游离铂和AUC水平比血液中高2至5倍,癌性腹膜炎患者则高7至14倍。(摘要截断于250字)

相似文献

1
[Usefulness of intraperitoneal carboplatin administration-- pharmacokinetic analysis].腹腔内给予卡铂的效用——药代动力学分析
Nihon Sanka Fujinka Gakkai Zasshi. 1992 Sep;44(9):1180-6.
2
[The pharmacokinetics of intraperitoneal (IP) carboplatin (CBDCA) and dose-up study of intravenous (IV) cyclophosphamide (CPM) in combination with IP CBCDA for advanced ovarian cancer patients].[晚期卵巢癌患者腹腔内注射卡铂(CBDCA)的药代动力学及静脉注射环磷酰胺(CPM)联合腹腔内注射卡铂的剂量递增研究]
Gan To Kagaku Ryoho. 1992 Dec;19(14):2373-9.
3
[Pharmacokinetics of carboplatin after intraperitoneal administration and clinical effect in ovarian cancer].[腹腔注射卡铂的药代动力学及对卵巢癌的临床疗效]
Gan To Kagaku Ryoho. 1992 Dec;19(14):2355-61.
4
Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.作为一种全身化疗方法,腹腔内输注卡铂可能比静脉给药在药理学上更为合理。一项由三开妇科研究组(SGSG)进行的研究,采用新的数学模型对腹腔内与静脉输注卡铂后铂的药代动力学进行比较分析。
Gynecol Oncol. 2005 Dec;99(3):591-6. doi: 10.1016/j.ygyno.2005.06.055. Epub 2005 Aug 10.
5
[Intraperitoneal high-dose cisplatinum chemotherapy (CDDP-ip) in patients with carcinomatous peritonitis].
Gan To Kagaku Ryoho. 1987 Apr;14(4):1025-32.
6
[Intraperitoneal chemotherapy using CBDCA for malignant gynecological tumors].
Gan To Kagaku Ryoho. 1992 Aug;19(10 Suppl):1738-41.
7
Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.基于药代动力学分析的卵巢癌患者术中腹腔内顺铂暴露情况的改善。
Cancer Chemother Pharmacol. 2008 Mar;61(3):415-21. doi: 10.1007/s00280-007-0484-x. Epub 2007 May 15.
8
[Chemotherapy in malignant gynecologic tumors using intraperitoneal catheter with a subcutaneous reservoir].
Gan To Kagaku Ryoho. 1991 Aug;18(11):1795-9.
9
[Antitumor effects of liposome-entrapped carboplatin (Lipo-CBDCA) after intraperitoneal administration in rats bearing carcinomatous peritonitis].
Gan To Kagaku Ryoho. 1995 Sep;22(11):1598-601.
10
[Pharmacokinetics of carboplatin in a patient under hemodialysis].
Gan To Kagaku Ryoho. 1994 Mar;21(4):547-50.